SLC5A2 and type 2 diabetes mellitus: Of the 71 T2DM patients admitted with DKA, 16 (22.5%) were on SGLT2 inhibitor treatment upon admission, of whom 10 were using empagliflozin and 6 were using dapagliflozin.